Você procurou por: phenylacetylglutamine (Inglês - Maltês)

adjustment based on urinary phenylacetylglutamine
aġġustament ibbażat fuq phenylacetylglutamine fl-awrina

adjustment based on plasma phenylacetate and phenylacetylglutamine
aġġustament ibbażat fuq phenylacetate u phenylacetylglutamine fil-plażma

in patients with impaired hepatic function the conversion of phenylacetate to phenylacetylglutamine may be relatively slower.
f’pazjenti b’indeboliment fil-funzjoni epatika il-konversjoni ta’ phenylacetate għal phenylacetylglutamine tista’ ddum relattivament aktar.

studies with high intravenous doses of phenylacetate showed non linear pharmacokinetics characterised by saturable metabolism to phenylacetylglutamine.
studji b’għotja ta’dożi għoljin fil-vina ta’ phenylacetate urew farmokinetika mhux lineari kkaraterizzata minn metaboliżmu saturabbli għal phenylacetylglutamine.

serum potassium should be monitored during therapy since renal excretion of phenylacetylglutamine may induce a urinary loss of potassium.
il-potassju fis-serum għandu jkun immonitorjat matul it-terapija minħabba li l-eskrezzjoni mill-kliewi ta’ phenylacetylglutamine tista’ tikkawża t-telf ta’ potassju mill-urina.

phenylacetate is a metabolically active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine which is then excreted by the kidneys.
phenylacetate hija sustanza metabolikament attiva li tingħaqad ma’ glutamine permezz ta’ acetylation biex jifforma phenylacetylglutamine li mbagħad jitneħħa mill-kliewi.

approximately 80 - 100 % of the medicinal product is excreted by the kidneys within 24 hours as the conjugated product, phenylacetylglutamine.
madwar 80 - 100% tal-prodott mediċinali jitneħħa mill-kliewi f’24 siegħa bħala prodott konjugat, phenylacetylglutamine.

excretion approximately 80-100% of the medicinal product is excreted by the kidneys within 24 hours as the conjugated product, phenylacetylglutamine.
6 eskrezzjoni madwar 80- 100% tal- prodott mediċinali jitneħħa mill- kliewi f’ 24 siegħa bħala prodott konjugat, phenylacetylglutamine.

after a single dose of 5 g of sodium phenylbutyrate, in the form of granules, measurable plasma levels of phenylacetate and phenylacetylglutamine are detected 30 and 60 minutes respectively after dosing.
wara doża waħda ta’ 5 g ta’ fenajlbutirajt ta’ sodium fil-forma ta’ granijiet , livelli li jitkejjlu fil- plażma ta’ phenylacetate u phenylacetylglutamine kienu osservati 30 u 60 minuta rispettivament wara l-għotja tad-doża.

on a molar basis, phenylacetylglutamine is comparable to urea (each containing 2 moles of nitrogen) and therefore provides an alternate vehicle for waste nitrogen excretion.
fuq bażi molari, phenylacetylglutamine jista’ jitqabbel ma’ l-urea (it-tnejn fihom żewġ moles ta’ nitrogen) u għalhekk jipprovdi metodu alternattiv għat-tneħħija mill-ġisem ta’ nitrogen mhux meħtieġ.

based on studies of phenylacetylglutamine excretion in patients with urea cycle disorders it is possible to estimate that, for each gram of sodium phenylbutyrate administered, between 0.12 and 0.15 g of phenylacetylglutamine nitrogen are produced.
skond studji li saru b’phenylacetateglutamine, it- tneħħija mill-ġisem f’pazjenti bi problemi fiċ-ċiklu ta’ l-urea, hu possibli li jkun stmat li, għal kull gramma ta’ sodium phenylbutyrate mogħti, jiġi prodott bejn 0.12 u 0.15 g ta’ phenylacetylglutamine nitrogen.

in normal volunteers gender differences were found in the pharmacokinetic parameters of phenylbutyrate and phenylacetate (auc and cmax about 30 - 50 % greater in females), but not phenylacetylglutamine.
f’voluntiera normali, differenzi fis-sess instabu fil-parametri farmakokinetiċi ta’ phenylbutyrate u phenylacetate (auc u cmax madwar 30 - 50% akbar fin-nisa) iżda mhux phenylacetylglutamine.